Hormonal
Semaglutide (2.4 mg weekly) produces significantly greater weight loss (15.8%) compared to liraglutide (6.4%) in patients without type 2 diabetes.
If you are struggling with weight loss despite diet and exercise, semaglutide (Wegovy) is currently the most effective registered medication, offering about 15.8% average weight loss over 68 weeks when combined with lifestyle changes. It is taken as a once-weekly injection, which is less frequent than daily options like liraglutide.
In the STEP 8 trial, comparing the effectiveness of semaglutide with liraglutide, patients were treated for 68 weeks. The liraglutide group experienced an average weight reduction of 6.4%, while the semaglutide group achieved a significantly higher average weight loss of 15.8%. [19]
Why this rating
Based on a specific randomized clinical trial (STEP 8) cited in the review.
Source
Pharmacological treatment of obesity: an overview of different groups of anti-obesity drugs available in Poland
Barbara Woch et al. · Journal of Education Health and Sport · 2024
DOI 10.12775/jehs.2024.58.004
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →